Literature DB >> 28093335

Intracoerulear microinjection of orexin-A induces morphine withdrawal-like signs in rats.

Masoumeh Ghaemi-Jandabi1, Hossein Azizi2, S Mohammad Ahmadi-Soleimani1, Saeed Semnanian3.   

Abstract

Orexin (hypocretin) neuropeptides play a pivotal role in expression of opioid withdrawal signs. Hypothalamic orexinergic neurons provide dense afferents for the nucleus locus coeruleus (LC). Somatic signs of opioid withdrawal are associated with the enhanced activity of LC neurons. In addition, intra-LC administration of orexin-A leads to the hyperactivity of LC neurons. The present study was an attempt to investigate whether intra-LC microinjection of orexin-A induces morphine withdrawal-like signs in both morphine dependent and control rats. To end this, adult male Wistar rats weighing 250-300g were used. For induction of morphine dependence, animals received morphine sulfate subcutaneously (10mg/kg, s.c.) at an interval of 12h for 9days. On day 10, intra-LC orexin injection (100μM, 200nl) was carried out two hours after last morphine administration. Morphine withdrawal-like signs were assessed in a transparent Plexiglas test chamber (30cm diameter, 50cm height) for 25min. Orexin-A microinjection induced some morphine withdrawal-like signs in both morphine dependent (chewing, scratching, rearing, teeth chattering, wet-dog shake and paw tremor) and control (chewing, scratching, rearing, sniffing, wet-dog shake and head tremor) rats. Furthermore, microinjection of SB-334867, a selective orexin type-1 receptor antagonist before orexin-A significantly suppressed orexin-induced morphine withdrawal-like signs. It seems that orexin-A, via increasing the activity of LC neurons, mediates the induction of some morphine withdrawal-like signs independent of morphine dependence.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Locus coeruleus; Morphine withdrawal-like signs; Opiate dependence; Orexin-A; Rat

Mesh:

Substances:

Year:  2017        PMID: 28093335     DOI: 10.1016/j.brainresbull.2017.01.010

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  8 in total

1.  Decrease of inhibitory synaptic currents of locus coeruleus neurons via orexin type 1 receptors in the context of naloxone-induced morphine withdrawal.

Authors:  Mahnaz Davoudi; Hossein Azizi; Javad Mirnajafi-Zadeh; Saeed Semnanian
Journal:  J Physiol Sci       Date:  2018-11-07       Impact factor: 2.781

2.  Reduction of Orexin-A Is Associated With Anxiety and the Level of Depression of Male Methamphetamine Users During the Initial Withdrawal Period.

Authors:  Lei Guo; Aqian Hu; Xiaoxi Zhao; Xiaojun Xiang
Journal:  Front Psychiatry       Date:  2022-07-04       Impact factor: 5.435

Review 3.  Noradrenergic circuits and signaling in substance use disorders.

Authors:  Anthony M Downs; Zoe A McElligott
Journal:  Neuropharmacology       Date:  2022-02-14       Impact factor: 5.273

Review 4.  Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date.

Authors:  Reda M Chalhoub; Peter W Kalivas
Journal:  Drugs       Date:  2020-10       Impact factor: 9.546

5.  Persistent effects of the orexin-1 receptor antagonist SB-334867 on motivation for the fast acting opioid remifentanil.

Authors:  Aida Mohammadkhani; Morgan H James; Caroline B Pantazis; Gary Aston-Jones
Journal:  Brain Res       Date:  2019-09-14       Impact factor: 3.252

6.  Oleanolic Acid Attenuates Morphine Withdrawal Symptoms in Rodents: Association with Regulation of Dopamine Function.

Authors:  Zhiqi Shi; Shugang Pan; Luolin Wang; Sha Li
Journal:  Drug Des Devel Ther       Date:  2021-08-24       Impact factor: 4.162

7.  OX2R-selective orexin agonism is sufficient to ameliorate cataplexy and sleep/wake fragmentation without inducing drug-seeking behavior in mouse model of narcolepsy.

Authors:  Hikari Yamamoto; Yasuyuki Nagumo; Yukiko Ishikawa; Yoko Irukayama-Tomobe; Yukiko Namekawa; Tsuyoshi Nemoto; Hiromu Tanaka; Genki Takahashi; Akihisa Tokuda; Tsuyoshi Saitoh; Hiroshi Nagase; Hiromasa Funato; Masashi Yanagisawa
Journal:  PLoS One       Date:  2022-07-22       Impact factor: 3.752

8.  Pharmacological characterization of a novel potent, selective, and orally active orexin 2 receptor antagonist, SDM-878.

Authors:  Shunsuke Maehara; Natsuko Yuge; Chika Higashi; Takumi Ota; Junji Furukawa; Takashi Takeuchi
Journal:  Neuropsychopharmacol Rep       Date:  2020-04-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.